Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing novel therapeutics for nonalcoholic steatohepatitis (NASH), a chronic liver disease with a significant unmet need. Their lead product, Rezdiffra (resmetirom), is the first FDA-approved treatment for NASH with moderate to advanced liver fibrosis. This once-daily oral therapy targets the underlying causes of NASH by reducing liver fat, inflammation, cell death, and fibrosis. Madrigal has a strong commitment to ethical and compliant practices and is actively working with key stakeholders to improve care for patients with NASH.

Madrigal is committed to improving care for patients with NASH through its research and development efforts. They have a robust clinical development program, multiple Phase 3 studies evaluating their therapy, and are actively involved in the NASH community through partnerships with patient advocacy organizations and education initiatives. Their leadership team boasts individuals with proven track records in developing FDA-approved medicines and building successful biopharmaceutical companies. They have established a comprehensive compliance program and a strong commitment to ethical and compliant practices.

Madrigal Pharmaceuticals offers flexible paid time off, which allows employees to have a greater sense of autonomy in managing their work-life balance. The company also offers a comprehensive benefits package that includes medical, dental, and vision insurance, as well as life and disability insurance. This suggests that employees have access to a range of benefits that contribute to their overall well-being and flexibility.

Madrigal Pharmaceuticals offers a comprehensive benefits package to its employees, including flexible paid time off, medical, dental, and vision insurance, as well as life and disability insurance. The company also offers a 401k plan with a match, and may offer bonus and equity opportunities depending on the role.

Madrigal Pharmaceuticals is a biopharmaceutical company dedicated to developing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with a high unmet medical need. They are focused on improving care for patients with NASH by targeting the underlying causes of the disease, aiming to reduce or eliminate liver fat, inflammation, and fibrosis. Madrigal's ambitious research programs have led to the first FDA-approved treatment for NASH, with ongoing research exploring further therapeutic advancements in this crucial area of healthcare.

Madrigal Pharmaceuticals fosters a culture of collaboration and innovation, emphasizing a commitment to improving care for patients with NASH. The company values a diverse and inclusive work environment, promoting teamwork, transparency, and a patient-centric mindset. This culture is reflected in the company's leadership team, which is comprised of individuals with proven track records in developing FDA-approved medicines and building successful biopharmaceutical companies.

Madrigal Pharmaceuticals is committed to fostering an inclusive and diverse workplace where all employees feel valued, respected, and empowered to contribute their unique talents. They strive to create an environment that embraces different perspectives, backgrounds, and experiences, recognizing that diversity strengthens their company culture and innovation. Madrigal is an Equal Opportunity Employer and prohibits discrimination based on race, ethnicity, color, religion, sex, gender identity, sexual orientation, national origin, age, disability, protected veteran or disabled status, or other characteristic protected by applicable federal, state, or local law.